Anaplastic lymphoma kinase is expressed in different subtypes of human breast cancer
| Autor: | Thomas F. Deuel, Joanne E. Mortimer, Yunchao Chang, Pablo Perez-Pinera, Aurora Astudillo |
|---|---|
| Rok vydání: | 2007 |
| Předmět: |
Biophysics
Breast Neoplasms Biology Pleiotrophin Biochemistry Article Gene Expression Regulation Enzymologic Breast cancer hemic and lymphatic diseases Tumor Cells Cultured medicine Humans Anaplastic lymphoma kinase Anaplastic Lymphoma Kinase Tissue Distribution Molecular Biology Anaplastic large-cell lymphoma Receptor-Like Protein Tyrosine Phosphatases Class 5 Receptor Protein-Tyrosine Kinases Cancer Cell Biology Protein-Tyrosine Kinases medicine.disease Gene Expression Regulation Neoplastic Tumor progression Cancer cell Cancer research Cytokines Protein Tyrosine Phosphatases Signal transduction Carrier Proteins |
| Zdroj: | Biochemical and Biophysical Research Communications. 358:399-403 |
| ISSN: | 0006-291X |
| DOI: | 10.1016/j.bbrc.2007.04.137 |
| Popis: | Pleiotrophin (PTN, Ptn) is an 18kDa cytokine expressed in human breast cancers. Since inappropriate expression of Ptn stimulates progression of breast cancer in transgenic mice and a dominant negative PTN reverses the transformed phenotype of human breast cancer cells that inappropriately express Ptn, it is suggested that constitutive PTN signaling in breast cancer cells that inappropriately express Ptn activates pathways that promote a more aggressive breast cancer phenotype. Pleiotrophin signals by inactivating its receptor, the receptor protein tyrosine phosphatase (RPTP)beta/zeta, and, recently, PTN was found to activate anaplastic lymphoma kinase (ALK) through the PTN/RPTPbeta/zeta signaling pathway in PTN-stimulated cells, not through a direct interaction of PTN with ALK and thus not through the PTN-enforced dimerization of ALK. Since full-length ALK is activated in different malignant cancers and activated ALK is a potent oncogenic protein, we examined human breast cancers to test the possibility that ALK may be expressed in breast cancers and potentially activated through the PTN/RPTPbeta/zeta signaling pathway; we now demonstrate that ALK is strongly expressed in different histological subtypes of human breast cancer; furthermore, ALK is expressed in both nuclei and cytoplasm and, in the ;;dotted" pattern characteristic of ALK fusion proteins in anaplastic large cell lymphoma. This study thus supports the possibility that activated ALK may be important in human breast cancers and potentially activated either through the PTN/RPTPbeta/zeta signaling pathway, or, alternatively, as an activated fusion protein to stimulate progression of breast cancer in humans. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect